Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 15 of 19 for:    "Hypogonadism" | "Calcium, Dietary"

Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors (T&D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02419105
Recruitment Status : Recruiting
First Posted : April 17, 2015
Last Update Posted : September 10, 2019
Sponsor:
Collaborators:
Swiss National Science Foundation
Besins Healthcare (funding: investigator-initiated and independent grant)
Dr. Wild & Co. (funding: investigator-initiated and independent grant)
Cantonal Hospital of St. Gallen (PD Dr. Thomas Müntzer)
Tufts University Jean Mayer USDA Human Nutrition Research Center on Aging
Centre on Ageing and Mobility (Dr. Andreas Egli)
University Hospital of Zurich, Dept. of Geriatrics (Prof. Robert Theiler, Dr. Gregor Freystaetter)
Information provided by (Responsible Party):
University of Zurich

Brief Summary:
The overall purpose of this study is to test the individual and combined effect of transdermal testosterone and/or Vitamin D in reducing fall risk and improve function in pre-frail hypogonadal senior men.

Condition or disease Intervention/treatment Phase
Hypogonadism Pre-frail Seniors Drug: Testosterone Drug: Colecalciferol Drug: Placebo drink solution Drug: Placebo transdermal gel Phase 3

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 168 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors. Double Blind, 2x2 Factorial, Randomized Placebo-‐Controlled Clinical Trial
Study Start Date : September 2015
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : March 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Falls Vitamin D

Arm Intervention/treatment
Active Comparator: Testosterone + Vitamin D
Testosterone, transdermal gel, 75 mg, once per day, for 12 months AND Colecalciferol, oral drink solution, 24000 IU, once per month, for 12 months
Drug: Testosterone
transdermal gel, 75 mg daily
Other Name: ATC code: G03BA03

Drug: Colecalciferol
drink solution, 24000 IU once per month
Other Name: Vitamin D3, CAS No: 67-97-0, ATC code: A11CC05

Active Comparator: Testosterone + Placebo
Testosterone, transdermal gel, 75 mg, once per day, for 12 months AND Placebo: Colecalciferol, oral drink solution, 0 IU, once per month, for 12 months
Drug: Testosterone
transdermal gel, 75 mg daily
Other Name: ATC code: G03BA03

Drug: Placebo drink solution
drink solution, 0 IU Colecalciferol once per month

Active Comparator: Placebo + Vitamin D
Placebo: Testosterone, transdermal gel, 0 mg, once per day, for 12 months AND Colecalciferol, oral drink solution, 24000 IU, once per month, for 12 months
Drug: Colecalciferol
drink solution, 24000 IU once per month
Other Name: Vitamin D3, CAS No: 67-97-0, ATC code: A11CC05

Drug: Placebo transdermal gel
transdermal gel, 0 mg testosterone daily

Placebo Comparator: Control
Placebo: Testosterone, transdermal gel, 0 mg, once per day, for 12 months AND Placebo: Colecalciferol, oral drink solution, 0 IU, once per month, for 12 months
Drug: Placebo drink solution
drink solution, 0 IU Colecalciferol once per month

Drug: Placebo transdermal gel
transdermal gel, 0 mg testosterone daily




Primary Outcome Measures :
  1. Number of fallers [ Time Frame: 12 months ]
    The participant will fill in a falls diary.

  2. Rate of falls [ Time Frame: 12 months ]
    The participant will fill in a falls diary.


Secondary Outcome Measures :
  1. Appendicular lean skeletal muscle mass (aLSM) [ Time Frame: 12 months ]
    measured by dual energy X-ray absorptiometry (aLSM is defined as of skeletal muscles in upper and lower extremities)

  2. Lower extremity function [ Time Frame: 12 months ]
    assessed with the Short Physical Performance Battery (SPPB)

  3. Reaction time [ Time Frame: 12 months ]
    assessed by repeated sit-to-stand test (part of the SPPB)

  4. Gait Speed [ Time Frame: 12 months ]
    assessed by 4 meter walk test (part of the SPPB)

  5. Quality of life [ Time Frame: 12 months ]
    assessed by EuroQol (EQ5D-3L)


Other Outcome Measures:
  1. Cognitive function [ Time Frame: 12 months ]
    assessed by the Montreal Cognitive Assessment (MoCA) test

  2. Body composition [ Time Frame: 12 months ]
    measured by dual energy X-ray absorptiometry

  3. Hip bone density [ Time Frame: 12 months ]
    measured by dual energy X-ray absorptiometry

  4. Incidence of sarcopenia [ Time Frame: 12 months ]
    Since there is no consensus on a universally accepted definition of sarcopenia to date, all previously used and newly proposed composite definitions of sarcopenia based on lean mass and the SPPB, its components and/or grip strength, will be considered.

  5. Bone quality (bone micro-architecture and bone strength) [ Time Frame: 12 months ]
    measured by high-resolution peripheral quantitative computed tomography (XtremeCT)

  6. serum concentrations of 25(OH)D [ Time Frame: 12 months ]
    Adherence, Laboratory measures at the Institute of Clinical Chemistry at the University Hospital Zürich

  7. free and bioavailable testosterone (serum concentration of total testosterone, sex hormone binding globulin, albumin) [ Time Frame: 12 months ]
    Adherence, Laboratory measures at the Institute of Clinical Chemistry at the University Hospital Zürich, total testosterone will be measured, free and bioavailable testosterone will be calculated

  8. haemoglobin, haematocrit, prostate-specific antigen, calcium, creatinine, alanine aminotransferase, aspartate aminotransferase, Gamma-glutamyl transferase, alkaline phosphatase [ Time Frame: 12 months ]
    Laboratory measures at the laboratory of the City Hospital Waid, Zürich

  9. Incidence of cardiovascular adverse events [ Time Frame: 12 months ]
    "cardiovascular event" defined as: myocardial infarction, stroke, revascularization procedure of coronary artery bypass graft and percutaneous coronary intervention, incident congestive heart disease (heart insufficiency), cardiovascular mortality



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men with documented total testosterone levels < 11.30 nmol/l
  2. Able to come to the study centre (Community-dwelling or institutionalized)
  3. Age 65+ years
  4. At a higher risk for falling
  5. Body mass index > 18.0 and < 35.0 kg/m2
  6. Understands German in reading and writing plus able to read, understand, and complete questionnaires and tests.
  7. Willingness to limit additional vitamin D3 intake to a maximum of 800 IU per day
  8. Willingness to limit calcium supplement intake to 500 mg/day
  9. Willingness to stop active vitamin D metabolites
  10. Willingness to forgo any additional use/application of testosterone products for the duration of the trial.
  11. Participant understands the study procedures, alternative treatments available and risks involved with the study and voluntarily agrees to participate by giving a written informed consent.
  12. Participant meets the routine clinical laboratory safety screening tests performed at screening visit.
  13. Participant is able and willing to perform all study tests, attend all required office visits, and provide blood and urine samples.
  14. Participant is able to apply the testosterone/placebo gel and is able to drink the vitamin D/placebo solution.
  15. Participant is mentally competent (judicious) defined by having score > 24 on the Folstein's mini mental state examination (MMSE) at the screening visit.

Exclusion Criteria:

  1. Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product
  2. Treatment with vitamin K-antagonists, insulin, adrenocorticotropic hormone (ACTH), corticosteroid (>5mg/d)
  3. Elevated (≥ 4.0 ng/ml) prostate-specific antigen levels (at screening) and/or palpable signs of prostate cancer
  4. Palpable signs of breast-cancer
  5. Haemoglobin ≤ 100 g/l
  6. Haematocrit ≥ 0.50 L/L
  7. Liver function values (alanine aminotransferase, aspartate aminotransferase, Gamma-glutamyl transferase, alkaline phosphatase) more than 3 times the upper limit of normal.
  8. Consumption of >800 IU vitamin D on any day in the 6 months prior to enrolment. Provision: a person can be enrolled as soon as the mean intake in the last 6 months and since the last dose is ≤ 800 IU.
  9. Elevated serum calcium ≥ 2.60 mmol/l (adjusted for albumin )
  10. Estimated (Cockcroft and Gault formula ) creatinine clearance ≤ 30 ml/min
  11. Severe visual or hearing impairment
  12. History of cancer < 5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer
  13. Myocardial infarction in the last 3 months, unstable angina pectoris and/or exertional dyspnoea >=NYHA III
  14. Treatment worthy but untreated sleep apnoea or chronic (obstructive) pulmonary disease, epilepsy
  15. Significant end-stage disease, i.e. genitourinary, cardiovascular, hepatic, renal, endocrine, hematologic, psychiatric, or pulmonary disease, which, in the opinion of the investigator, may pose a high risk to the patient or impair the patient's ability to complete the trial or confound the results
  16. Uncontrolled hypertension (blood pressure mm Hg ≥ 180 systolic or ≥ 110 diastolic)
  17. Alcohol abuse or alcoholic disease
  18. Participation in another interventional research trial within the last 6 months prior to screening
  19. Severe gait impairment, e.g. due to Parkinson's disease or hemiplegia
  20. Previous enrolment into the current study
  21. Enrolment of the investigator, his/her family members, employees and other dependent persons

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02419105


Contacts
Layout table for location contacts
Contact: Heike A Bischoff-Ferrari, MD, DrPH +41442552699 heike.bischoff@usz.ch

Locations
Layout table for location information
Switzerland
Dept. of Geriatrics and Aging Research, University of Zurich / Geriatric Clinic University Hospital Zurich Recruiting
Zürich, ZH, Switzerland, 8037
Contact: Heike A Bischoff-Ferrari, MD, DrPH    (+41)44 2552699    Heike.Bischoff@usz.ch   
Principal Investigator: Heike A Bischoff-Ferrari, MD, DrPH         
Sub-Investigator: Andreas Egli Linder, MD         
Sponsors and Collaborators
University of Zurich
Swiss National Science Foundation
Besins Healthcare (funding: investigator-initiated and independent grant)
Dr. Wild & Co. (funding: investigator-initiated and independent grant)
Cantonal Hospital of St. Gallen (PD Dr. Thomas Müntzer)
Tufts University Jean Mayer USDA Human Nutrition Research Center on Aging
Centre on Ageing and Mobility (Dr. Andreas Egli)
University Hospital of Zurich, Dept. of Geriatrics (Prof. Robert Theiler, Dr. Gregor Freystaetter)
Investigators
Layout table for investigator information
Principal Investigator: Heike A Bischoff-Ferrari, MD, DrPH University of Zurich

Layout table for additonal information
Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT02419105     History of Changes
Other Study ID Numbers: T&D Study
32003B_135192 ( Other Grant/Funding Number: Swiss National Science Foundation )
SNCTP: 000001224 ( Registry Identifier: Swiss Clinical Trials Portal )
KEK-ZH-2014-0436 ( Other Identifier: Cantonal Ethics Committee Zurich, Switzerland )
2105DR3024 ( Other Identifier: Swiss Agency for Therapeutic Products (Swissmedic) )
First Posted: April 17, 2015    Key Record Dates
Last Update Posted: September 10, 2019
Last Verified: September 2019
Keywords provided by University of Zurich:
Falls
hypogonadal men
Seniors
Testosterone
Colecalciferol
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypogonadism
Calcium-Regulating Hormones and Agents
Gonadal Disorders
Endocrine System Diseases
Vitamin D
Ergocalciferols
Cholecalciferol
Vitamins
Methyltestosterone
Pharmaceutical Solutions
Testosterone
Testosterone undecanoate
Testosterone enanthate
Testosterone 17 beta-cypionate
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Androgens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents